Human Insulin-like Growth Factor I (hIGF-I)

• 产品编号：CST-8917SC      品牌：CST       原厂货号：8917SC
• 产品分类：蛋白质检测与分析 > 蛋白质，多肽和酶 > 细胞因子和生长因子 > IGF 胰岛素样生长因子及其结合蛋白
• 应用分类：

描述：

CST公司生产的人源重组蛋白IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343)是从大肠杆菌细胞表达而来。重组的hIGF-I蛋白在末端有Met标签，其分子量据推算为7,785Da。DTT-降解蛋白作为一个6kDa的蛋白而转移。重组hIGF-I蛋白的N-末端MGPET的序列通过测序得到。6 μg 还原 (+) 和 非还原的(-) hIGF-I通过SDS-PAGE检测，纯度大于98%，所有批次的纯度均高于98%。重组蛋白hIGF-I的生物活性是通过人源皮肤成纤维细胞的增殖实验确定的。每个批次的ED50值在2-8 ng/ml之间。内毒素含量：小于0.01 ng /1 μg hIGF-I。

有载体: 每微克hIGF-I蛋白溶解在包含 100 mM NaCl 和 20 μg BSA的柠檬酸盐（pH 3.0）溶液中，并通过 0.22 μm 滤膜冻干。

无载体: 每微克hIGF-I蛋白溶解在包含 100 mM NaCl 的柠檬酸盐（pH 3.0）溶液中，并通过 0.22 μm 滤膜冻干。

大多数的循环的内分泌IGF-I是通过肝细胞产生的, 旁分泌或自分泌的IGF-I 是由特定细胞类型在特定的组织中产生(1,2)。 许多肿瘤细胞能产生IGF-I而调控很多的细胞活动，包括能量代谢、细胞增殖和细胞存活(3,4)。 IGF-I的活性是通过六个胞外IGF结合蛋白(IGFBPs)中的一个或多个共同调控。 IGFBPs结合到IGF-I上抑制IGF-I 和IGF-I 受体 (IGFIR)的结合 (1,2)。有些IGFBPs 能加强细胞对IGF-I的响应。IGF-I 结合到 IGFIR上激活了 Akt, JNK和Erk 信号通路 (2). IGF-I 和 IGFIR 通常被癌细胞频繁的表达，可能对某些种类的癌细胞的增殖和生存能力有重要的作用(1,2)。

原厂资料：

Source / Purification

Recombinant human IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343) was produced in E. coli at Cell Signaling Technology.

Molecular Characterization

Recombinant hIGF-I has a Met on the amino terminus and has a calculated MW of 7,785. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MGPET of recombinant hIGF-I was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-I. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hIGF-I was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 2-8 ng/ml.

Endotoxin

Less than 0.01 ng endotoxin/1 μg hIGF-I.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hIGF-I. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Background

Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I and most inhibit IGF-I binding to IGF-I receptor (IGFIR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGFIR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2).

注意事项：

Storage: Stable in lyophilized state at 4ºC for 1 year after
receipt. Sterile stock solutions reconstituted with carrier protein
are stable at 4ºC for 2 months and at -20ºC for 6 months. Avoid
repeated freeze-thaw cycles.